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José M. González-Navajas1,2*, Eyad Elkord3 and Jongdae Lee4
1 Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, 2 Department of Pharmacology, University
Miguel Hernández (UMH), Elche, Spain, 3 School of Science, Engineering and Environment, University of Salford,
Manchester, United Kingdom, 4 School of Basic Medical Sciences and State Key Laboratory of Respiratory Disease,
Guangzhou Medical University, Guangzhou, China
Keywords: CD4, immunotherapy, immune checkpoint inhibitor (ICI), cancer, T lymphocyte
Editorial on the Research Topic
CD4+ T Cells in Cancer Immunotherapies
In the last 20 years, remarkable advances in the field of immunotherapy have led to new therapeutic
options for patients with a wide range of cancer types. Among the different immunotherapy
approaches, immune checkpoint inhibition (ICI) therapy and chimeric antigen receptor (CAR) T
cells have arguably shown the greatest potential. All immunotherapies share a common goal, which
is to activate T lymphocytes and reinvigorate immune surveillance against cancer. While the role of
CD8+ T lymphocytes and other cytotoxic cells in tumor immunology has been extensively studied,
the importance of CD4+ T helper (Th) cells has been traditionally underestimated. In this special
Research Topic, the relationship between different CD4+ T cell subsets and the efficacy of current
cancer immunotherapies has been highlighted by several reviews and an original article.
A review article by Zuazo et al. puts systemic CD4+ T cells in the spotlight of PD1/PD-L1
blocking therapies, with a special focus on non-small cell lung cancer (NSCLC). Rather than
changes in the tumor microenvironment, the authors bring attention to the often overlooked but
significant impact that these therapies exert over systemic immunity. Pharmacodynamic changes in
circulating PD1+ CD8+ T cells after anti-PD-1 treatment have been correlated with clinical response
(1) and recent evidence suggests that these changes, in turn, may depend on systemic CD4+ cells (2).
Hence, Zuazo et al. argue that targeting systemic CD4 immunity might be an important element of
PD1-based therapies and propose that pre-treatment levels of specific CD4+ T cell memory subsets
in the periphery are correlated with response in NSCLC.
DeRogatis et al. review the role of PSGL-1 (P-selectin glycoprotein ligand-1) as an immune
checkpoint of CD4+ T cells. PSGL-1 is highly expressed in CD4+ T cells and binds to multiple
proteins including P-selectin and VISTA. Psgl-1-/- mice mount a potent CD4+ and CD8+ T cell
response against melanoma tumors compared to control mice. It is proposed that they energize
CD8+ T cells by targeting PSGL-1 in CD4+ T cells or target PSGL-1 along with anti-PD-1/PD-L1
and/or anti-CTLA-4.
Successful ICI therapy requires appropriate effector Th responses. The diverse and sometimes
opposing roles of effector Th cells, in particular Th1, Th9, and Th17 cells, has also been reviewed in
an article by Lee et al. The process of Th cell differentiation allows for considerable plasticity among
different Th subpopulations, which may be exploited to increase the efficacy of ICI therapy. For this
strategy to work, more data are necessary to clearly determine what type of Th subpopulation is
beneficial in each particular cancer type, and then identify suitable approaches to convert other Th
populations into that population. In a related article, Basu et al. discuss ways to exploit the opposingorg September 2021 | Volume 12 | Article 7376151
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They extensively document the roles that dendritic cells (DCs)
play during Th differentiation and CD8+ T cell functions and
propose that combinatorial approaches can drive multiple Th
subtypes to overcome potential obstacles to immunotherapy
such as a hostile tumor microenvironment (TME), presence of
inhibitory T cell populations and immune checkpoint receptors.
Some of these approaches to regulating CD4+ T cell function in
the TME might be based on epigenetic processes. Epigenetic
regulation is involved in Th cell differentiation and plasticity
both in homeostasis and in pathological conditions, such as
inflammatory bowel disease (3). In this Research Topic, Renaude
et al. discuss how epigenetic manipulation may induce a
favorable immune context in the TME and improve the
efficacy of immunotherapies, including adoptive cell transfer,
anti-cancer vaccines, and ICI therapy.
While certain Th subpopulations can boost the anti-tumor
immune response, one of the major hurdles of current cancer
immunotherapies is the presence of regulatory T (Treg) cells in
the TME. Treg cells not only accumulate in tumors but also show
a higher immunosuppressive capacity than their non-
intratumoral counterparts (4). González-Navajas et al. review
current understanding of how Treg cells inhibit anti-cancer
immunity and ICI therapy and discuss several strategies to
specifically deplete intratumoral Tregs or to convert them into
effector T cells without inducing systemic inflammation.Frontiers in Immunology | www.frontiersin.org 2Although important advances have been made in this
direction, a precise characterization of Treg cell populations
and identification of intratumoral Treg-specific targets in each
cancer type are still needed. In this sense, an original article by Di
Giorgio et al. reports a new molecular mechanism that controls
Treg suppressive abilities. The authors show that loss of the
transcription factor monocyte enhancement factor 2c (Mef2c) in
Foxp3+ Treg cells switches on the transcription of histone
deacetylase 9 (Hdac9), which in turn blocks Mef2d, a
transcription factor that sustains Treg suppressive functions
(5). Thus, Mef2c deletion led to the impairment of Treg cells
in vivo and enhanced anti-tumor immunity in a syngeneic lung
cancer model. Of note, Hdac9 is induced by Mef2d as part of a
negative feedback loop (6). Thus, Di Giorgio et al. propose a
mechanism whereby two members of the Mef2 family, Mef2c
and Mef2d, coordinate to turn the expression of Hdac9 on and
off and support Treg immune suppressive functions.
In conclusion, the papers included in this Research Topic
highlight the distinct contribution of different CD4+ T cell
populations to cancer immune surveillance and immunotherapy.AUTHOR CONTRIBUTIONS
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